This review summarizes recent findings on the regulation of vascular tone by the nuclear receptor transcription factor, peroxisome proliferator activated receptor (PPAR) g. Much of the recent work utilizes genetic tools to interrogate the significance of PPARg in endothelial and smooth muscle cells and novel PPARg target genes have been identified.
INTRODUCTION
The purpose of this review is to highlight mechanisms by which peroxisome proliferator activated receptor (PPAR) g regulates vascular tone. Vascular tone is a key determinant of systemic vascular resistance and local tissue perfusion. It is dependent on the function of the endothelium, smooth muscle cells and to some extent on the perivascular adipose tissue (PVAT). As vascular cell type specific functions of PPARg have just started to emerge, the authors will discuss key findings from previous studies that provide insights into the mechanisms of PPARg action. We will focus the review on the function of PPARg in endothelial and smooth muscle cells, particularly mechanisms uncovered by the use of genetically engineered mice as models to overcome the limitations of systemic thiazolidinedione (TZD) administration. Overall, numerous reports consistently support the concept that vascular PPARg is protective.
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR g AND MECHANISM OF ACTIONS
PPARg is a nuclear hormone receptor transcription factor. Two human PPARg isoforms have been identified, PPARg1 and PPARg2, which differ by a 30-amino acid extension at the N terminus. PPARg2 (the longer form) is highly expressed in adipose tissue, in which its function is a prerequisite for adipogenesis [1] . PPARg1 is ubiquitously expressed at a low level in other tissues in which it exerts cellspecific functions. PPARg in macrophages regulates immune defence through the regulation of a distinct set of genes, with a little overlap with PPARgtarget genes in adipocytes [2] .
PPARg regulates gene expression by forming a heterodimeric complex with the retinoid X receptor (RXR) at the PPAR response elements (PPRE). Without the ligand, the transcription of PPARg target genes is repressed due to the interaction of PPARg with corepressor complexes. Upon ligand binding, PPARg undergoes a conformational change in the ligand-binding domain and promotes gene expression through recruitment of a coactivator complex [1, 3] .
CLUES TO PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR g REGULATED BLOOD PRESSURE AND VASCULAR FUNCTION
The evidence that implicates PPARg in the regulation of cardiovascular homeostasis comes primarily from the observations that TZD, potent PPARg agonists, lower blood pressure and alleviate cardiovascular diseases [4] and patients with some PPARg mutations develop severe early-onset hypertension [5] . However, the molecular mechanism and the site of action for PPARg-mediated blood pressure regulation requires further investigation.
TZDs are high-affinity synthetic ligands of PPARg, previously used to treat patients with type 2 diabetes. The effectiveness of the TZD class in regulating glycemic control occurs through multiple mechanisms, including augmented b-cell function and enhanced insulin sensitivity in skeletal muscle, adipocyte and liver [6 && ]. Induction of adiponectin, fibroblast growth factor family (FGF) 1 and FGF21 by TZD were reported to be important mediators for the insulin sensitizing effect of a TZD [3, [7] [8] [9] . In combination, the activation of these mechanisms by TZD provides a long-lasting glycemic control compared with sulfonylureas and metformin [6 && ]. However, reports of serious adverse events, including weight gain, congestive heart failure, fluid retention and osteoporosis, have limited the clinical usefulness of TZD. The controversy was sparked in 2007 by a meta-analysis that reported the association of rosiglitazone with an increased risk of myocardial infarction and cardiovascular deaths [10] . Despite the limitations of meta-analysis, this study raised serious public concerns and the prescription of rosiglitazone was subsequently restricted. As of last year, the U.S. Foods and Drugs Administration (FDA) recommended that this restriction be removed after an independent re-adjudication showed no cardiovascular harms associated with the use of rosiglitazone [11 && ]. Although the results were not significantly different, fewer deaths from a cardiovascular cause were observed in patients who received rosiglitazone than those treated with metformin and sulfonylurea. Another member of the TZD class, pioglitazone has been shown to reduce cardiovascular outcomes in diabetic patients [11 && ]. It has been speculated that the improvement of lipid profile by pioglitazone might account for these differences [6 && ]. However, it is important to note that safety concerns reporting an increased risk of bladder cancer with pioglitazone have also been raised [12 && ]. Interestingly, multiple studies in human and animal models have shown that TZDs cause a modest decrease in both DBP and SBP, an effect that is not observed with other insulin sensitizer drugs [4] . It is interesting to note that TZD-mediated blood pressure lowering occurs despite edema and plasma volume expansion, implicating robust nonrenal actions of PPARg to lower blood pressure. Consistent with this is the observation that patients with some PPARg mutations exhibit severe early onset hypertension [5,13 && ,14,15] . This suggests the plausible hypothesis that there is a direct nonrenal action of PPARg, perhaps in the vasculature. That the same mutations also cause lipodystrophy, dyslipidemia, insulin resistance and type 2 diabetes argues either that the effects of the mutations are pleiotropic, that is, they target multiple tissues, or that the hypertension might be a secondary consequence from metabolic changes. A knock-in mouse model carrying the mouse equivalent to one of the PPARg mutations (P465L) originally identified in patients, exhibited
KEY POINTS
PPARg, a nuclear receptor, plays an important role in the vasculature, but the mechanisms remain under investigation.
Recent studies from genetically modified mouse models have emphasized the specific functions of PPARg in endothelial and smooth muscle cells, in which it provides a protective mechanism against cardiovascular diseases.
Endothelium PPARg modulates target genes expression involved with oxidative stress, inflammation and fatty acid transporters.
PPARg regulates genes in signaling cascades related to constriction and relaxation in smooth muscle.
PPARg may control the expression and activity of the renin-angiotensin in smooth muscle cells.
hypertension and cerebral arterial dysfunction despite normal insulin sensitivity, thus arguing against the latter [16] . This is further supported by studies in which PPARg activity was manipulated by deletion or overexpression of PPARg mutants in a vascular cell type specific manner that resulted in blood vessel dysfunction, independent of metabolic abnormalities [17-20,21 && ]. Moreover, transfection of vascular cells in vitro with two different mutants in PPARg (R165T and L339X), which were reported to cause severe hypertension in patients, recapitulated a robust induction of the renin-angiotensin system (RAS) and increased inflammation, and phenocopied what occurred in cells isolated from patients [13 && ]. Taken together, these studies reinforce the concept of the direct actions of PPARg in vascular cells.
ROLES OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR g IN ENDOTHELIUM
Many studies have shown that endothelial PPARg has anti-inflammatory and antioxidant actions, while promoting vasodilatation ( Fig. 1 ). TZD treatment of cultured vascular endothelial cells increases nitric oxide production via posttranslational modification of endothelial nitric oxide synthase (eNOS) [22] and preserves nitric oxide bioavailability through suppressing NADPH oxidase expression [23] . Activation of PPARg in the vasculature counteracts endothelin-1 induced constriction by induction of endothelin receptor type B expression in endothelial layers [24] . It was reported that endothelial PPARg is required for the blood pressure lowering effect of TZD [25, 26] . Endothelial-specific disruption of a conditional allele of PPARg (PPARg flox ) with Tie2-promoter driven Cre-recombinase (Tie2-Cre) resulted in mild hypertension and endothelial dysfunction that was associated with reduced nitric oxide production, increased reactive oxygen species and enhanced nuclear factor kappa B (NF-kB) activity [27] . In contrast, another study with Tie2-Cre-mediated PPARg disruption reported no change in systemic blood pressure at baseline but disrupted diurnal variations of blood pressure and heart rate [28] . Femoral arterial reactivity to phenylephrine, angiotensin II and KCl were significantly increased in Tie2Cre/PPARg flox mice [26] . Other phenotypes outside the vasculature were reported in studies using Tie2Cre, most likely because the promoter is active in cells other than endothelium [29, 30] . For Endothelial PPARg promotes vasodilation through enhanced nitric oxide (NO) production, increased NO bioavailability and decreased reactive oxygen species (ROS). Activation of PPARg in the vasculature counteracts endothelin-1 induced vasoconstriction by induction of ET B R expression. PPARg ameliorates inflammation in endothelial cells, perhaps through transrepression of NFkB. It has been shown that KLF11 is necessary for pioglitazone-mediated vascular protection following middle cerebral artery occlusion. KLF11 is a direct target of PPARg and also functions as a PPARg coregulator in cerebral vascular endothelial cells. Other evidence also suggests that PPARg in endothelial cells is important for metabolic balance and lipid accumulation in the periphery, possibly by regulating the fatty acid transporters, fatty acid translocase (CD36), fatty acid binding protein 4 (aP2) and retinol-binding protein (RBP)-7. ET B R, endothelin receptor type B; KLF-11, Kruppel-like factor-11; NF-kB, nuclear factor kappa light-chain enhancer of activated B cells; RXR, retinoid X receptor; SOD, Cu/Zn superoxide dismutase.
this reason, other investigators have utilized mice with vascular endothelial-cadherin (cdh5)-Cre recombinase-driven PPARg deletion. These mice showed aggravated ischemia-induced blood-brain barrier disruption due to cerebrovascular permeability, with no change in systemic blood pressure [31 && ]. Mechanistically, Kruppel-like factor (KLF)-11 has been identified as a PPARg gene target and was reported to function as a PPARg coregulator in cerebral vascular endothelial cells. Pioglitazonemediated vascular protection following middle cerebral artery occlusion was significantly lost in KLF11 null mice [31 && ]. Emerging evidence highlights the prominent role of endothelial PPARg during stress conditions. Transgenic mice expressing a dominant negative PPARg mutant (V290M or P467L), specifically in endothelium, exhibited reduced vasodilation to acetylcholine in the basilar artery and aorta after prolonged high-fat diet treatment [20] or during dyslipidemia induced by disruption of apolipoprotein E, but not at baseline [32 && ]. This impairment was restored by superoxide scavenger, suggesting increased oxidative stress caused by the loss of PPARg function. A significant increase in transcription of pro-oxidant genes such as p22phox, Noxo2 and NoxA2, concomitant with a reduction of mRNA of antioxidant catalase and Cu/Zn SOD, was observed in vascular endothelium from these mice [20] . This is consistent with catalase and Cu/Zn SOD being PPARg target genes [33, 34] . It is entirely possible that endogenous PPARg ligands, perhaps derived from free fatty acids, induce upregulation of these genes during high-fat feeding in normal mice, and this provides a protective mechanism. The downregulation of catalase and Cu/Zn SOD transcripts in the transgenic mice is potentially a direct consequence of the failure of endogenous PPARg ligands to increase the transcriptional activity of the V290M and P467L mutants of PPARg, which are located in the ligand-binding domain [15] .
Endothelial dysfunction is often superimposed with obesity and type 2 diabetes. A novel role for endothelial cells in energy storage through fatty acid release in and out of the peripheral tissues has started to emerge [35] . Indeed, classic PPARg transcriptional targets involved with fatty acid metabolism such as CD36, aP2 and RBP7 were shown to be expressed in endothelial cells [18] . Activation of PPARg in microvascular endothelial cells markedly increased expression of aP2 and CD36 [36 & ]. Downregulation of these fatty acid transporters mRNA in endothelium from endothelial-specific PPARg knockout mice was associated with dyslipidemia after high-fat overload [18,36 & ]. Unexpectedly, these mice manifested reduced white adipose tissue mass and improved insulin sensitivity following high-fat diet, effects that persisted even after reconstitution of hematopoietic cells in the endothelial-specific PPARg knockout, suggesting that endothelial PPARg is critical for metabolic balance and lipid accumulation in the periphery [18] . Despite improving insulin sensitivity, impaired vasorelaxation and hypertension following high-fat diet was observed [18] . These findings suggest that endothelial PPARg might regulate vascular function by targeting a set of genes distinct from those responsible for metabolism. This study also enforces the hypothesis that endothelial PPARg is required for vascular protection during fatty acid overload.
ROLES OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR g IN SMOOTH MUSCLE
The net signaling in smooth muscle initiated by neurohumoral factors as well as intrinsic properties of the vessels determine the tone of the vasculature (Fig. 2 ). Specific expression of dominant negative mutant PPARg (P467L) in smooth muscle cells of transgenic mice (termed S-P467L) resulted in hypertension, vascular dysfunction, cerebral arteriole remodeling, tachycardia and baroreflex dysfunction [19,37 && ]. Aberrant vascular reactivity is observed in both conduit and resistance arteries, emphasizing the critical role of PPARg in regulation of the blood vessel tone. In aorta and cerebral arteries, interference of PPARg contributed to loss of responsiveness to nitric oxide dependent vasorelaxation [38,39 && ]. Strikingly, the hypercontractile phenotype in response to receptor-dependent agonists is apparent in these transgenic mice. Inhibition of Rho kinase not only blunted the augmented constriction, but it also restored the impaired nitric oxide responsiveness in aorta and cerebral arteries from these transgenic mice [38,39 && ], which is consistent with aberrantly increased Rho kinase activity. Mechanistically, mutant PPARg led to a defect in RhoA degradation caused by a reduced expression of Cullin-3, a component of an E3-ubiquitin ligase complexmediating proteasomal degradation of different substrates including RhoA. In smooth muscle cells, downregulated Cullin-3 expression significantly increased RhoA [38] . Preincubation of isolated aorta from a normal mouse with a pan-Cullin inhibitor resulted in augmented vasoconstriction that was dependent on Rho kinase, resembling the phenotype observed in S-P467L aorta. RhoBTB1, a potential Cullin-3 adapter, was identified as a transcriptional target of PPARg and its expression was dramatically decreased by P467L mutant PPARg [38] . It remains unclear whether loss of this specific adapter contributes to suppression of Cullin-3 activity and reduced RhoA degradation.
The role of PPARg in the regulation of myogenic tone has also been reported. Myogenic tone is an intrinsic property of smooth muscle in resistance arterial beds. This mechanism allows precise control of local blood flow despite the fluctuation of systemic blood pressure. Inhibition of PPARg function mediated by dominant negative expression in smooth muscle (S-P467L) resulted in a marked increase in myogenic constriction in small mesenteric arteries. Augmented basal tone is attributable to a robust downregulation of the regulator of G protein signaling 5 (RGS5) mRNA and a subsequent increase in protein kinase C activity. Loss of RGS5 transcript in S-P467L mesenteric arteries is also associated with a selective increase in angiotensin II induced vasoconstriction and extracellular signalregulated kinases (ERK) 1/2 activation [40,41 & ], consistent with findings from RGS5 null mice [42 & ]. Several lines of investigation reveal that RGS5 is a novel PPARg target. For example, PPARg bound to a PPRE in the RGS5 locus and TZD increased RGS5 transcript, an effect that was completely lost in resistance vessels with dominant negative PPARg expression [40] . Downregulation of PPARg expression or activity has often been correlated with increased AT 1 receptor (AT 1 R) expression, and a recent study implicated hypoxia-inducible factor (HIF)-1a [43 & ]. Loss of HIF1a in smooth muscle resulted in suppressed PPARg expression and subsequent upregulation of AT 1 R, and smooth muscle specific HIF1a knockout mice exhibited augmented vasoconstriction to angiotensin-II and increased SBP. Recent clinical evidence also highlights the interaction between PPARg and the RAS. Patients with mutations in the DNA-binding domain (R165T) or ligand-binding domain (L339X, causing a truncation) of PPARg exhibited lipodystrophy, insulin resistance and severe hypertension. It is surprising to note that in addition to AT 1 R, other RAS components including renin and angiotensinogen were markedly increased in fibroblasts or blood mononuclear cells isolated from these patients [13 && ]. The authors reported that the effect of the mutations was reproduced in transfected vascular smooth muscle cells, which lead them to conclude that the induction of the RAS was due to a direct effect of loss of PPARg function. AT 1 R antagonist reportedly improved blood pressure control in these patients [13 && ], but blood vessel function was not studied. It is notable Smooth muscle PPARg is also important for normal myogenic tone via regulating regulator of G-protein signaling (RGS)-5 transcript. Furthermore, exacerbated responses to angiotensin II, either by upregulated angiotensin II receptor, type 1 (AT 1 R), or decreased RGS5, are observed when PPARg function is lost in smooth muscle cells and that potentially contributes to increased oxidative stress and vascular hypertrophy. In addition to AT 1 R, other evidence from newly identified PPARg mutants indicates that PPARg is critical in regulating renin and angiotensinogen expression. Transcription of b2 adrenergic receptor has also been reported to be regulated by smooth muscle PPARg, thereby promoting vasodilation. DAG, diacylglycerol (DAG); ERK1/2, mitogen-activated protein kinase; IP3, inositol trisphosphate; PKC, protein kinase C; PLC, phospholipase C; RhoA, Ras homolog family member A; Rho BTB-1, Rho-related BTB domain-containing protein-1; ROCK, Rho-associated protein kinase; RXR, retinoid X receptor.
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that AT 1 R has been recently shown to act as a mechanosensor [44 & ]. Although the mechanism whereby reduced PPARg activity leads to increased AT 1 R remains unclear, it is possible that increased AT 1 R in these patients may have contributed to increased myogenic tone, vascular dysfunction and oxidative stress.
Mice with lifelong PPARg deficiency specifically in smooth muscle (SM22Cre/PPARg flox ) exhibited slightly increased systemic blood pressure and impaired circadian variations of mean arterial pressure [28] . Another study [21 && ] with inducible smooth muscle specific PPARg inactivation in adult mice using smooth muscle myosin heavy chain promoter reported no difference in baseline blood pressure before or after angiotensin-II infusion compared with control mice. Interestingly, the mesenteric arteries from these mice exhibited exacerbated angiotensin-II induced endothelial dysfunction, vascular remodeling and inflammation [21 && ]. These findings are consistent with the hypothesis that smooth muscle PPARg is protective against hypertension and vascular dysfunction. In contrast to these studies, another line of smooth muscle PPARgdeficient mice generated by crossing PPARg flox mice with knock-in mice expressing Cre-recombinase in the endogenous SM22 gene locus manifested decreased blood pressure and enhanced vasodilation to b-adrenergic receptor [17] . The surprising and inconsistent results were potentially reconciled when the same author later reported that these mice completely lack PVAT resulting from the transient activation of SM22 promoter in PVAT during development [45] . Whereas it is entirely possible that loss of PVAT might contribute to discrepant results compared with other studies, it also underscores the potential importance of PVAT in regulating vascular tone.
NEW SURPRISES
The progressive work on the function of PPARg in the vasculature consistently supports the notion that PPARg is required to maintain homeostasis of the blood vessel (Figs 1 and 2) . Emerging evidence has recently revealed that the complexity of PPARg extends far beyond the classic view as a regulator of gene transcription. For example, PPARg was reported to act as an E3 ligase that promotes ubiquitination of p65, a subunit of NFkB, through a direct PPAR-p65 interaction to regulate inflammatory responses [46] . PPARgs activity as an E3 ligase for p65 would be functionally analogous, but mechanistically distinct from its better characterized transrepression of inflammatory gene transcription [47] . Other studies demonstrated that the activity of PPARg can be regulated by posttranslational modifications. This has become a very provocative topic of discussion and investigation. With relevance to the anti-inflammatory activities of PPARg, liganddependent sumoylation of PPARg inhibits proinflammatory gene targets of NFkB or AP1 through a transrepression mechanism [48] . The transcriptional activity of PPARg can also be modulated by phosphorylation and acetylation. Phosphorylation of PPARg at Ser273 selectively decreases the expression of a subset of genes involved with insulin sensitivity [49] . Deacetylation of PPARg at Lys268 and Lys293 is involved with browning of white adipose tissue, a phenomenon that promotes enhanced metabolism [50] . Thus, PPARg activity may not only be impaired by mutation but also under conditions which promote its posttranslation modification. Accordingly, it is entirely possible that the mediators often correlated with vascular diseases and hypertension, such as oxidative stress, angiotensin II and free fatty acids, are able to modify and impair PPARg activity via these mechanisms that further promotes vascular dysfunction.
CONCLUSION
Understanding the complexity of PPARg function, particularly in specific tissues or cell types, will help develop new classes of drugs that can either target PPARg or the physiological pathways it regulates more selectively. With new data suggesting that activation of PPARg in the brain and bone [12 && ] can contribute to weight gain and bone loss, respectively, there is a need for a new therapy that provides less accessibility to these tissues. Although it would be technically challenging to chemically activate PPARg selectively in the vasculature, it may be possible to selectively activate or inhibit some of the final common pathways regulated by PPARg in endothelium or smooth muscle.
